Histone H4K20 Trimethylation is Decreased in Murine Models of Heart Disease
S. M. Hickenlooper, K. Davis, H. Sheikh, M. Miller, R. Bia, S. Valdez, M. Szulik, S. Franklin
Abstract
Heart disease is the leading cause of death in the developed world, and its comorbidities such as hypertension, diabetes, and heart failure are accompanied by major transcriptomic changes in the heart. During cardiac dysfunction, which leads to heart failure, there are global epigenetic alterations to chromatin that occur concomitantly with morphological changes in the heart in response to acute and chronic stress. These epigenetic alterations include the reversible methylation of lysine residues on histone proteins. Lysine methylation on histone H3K4 and H3K9 were among the first methylated lysine residues identified and have been linked to gene activation and silencing, respectively. However, much less is known regarding other methylated histone residues, including histone H4K20. Trimethylation of histone H4K20 has been shown to repressive gene expression, however this mark has never been examined in the heart. Here we utilized immunoblotting and mass spectrometry to quantify histone H4K20 trimethylation in three models of cardiac dysfunction. Our results show that lysine methylation at this site is regulated in a biphasic manner leading to increased H4K20 trimethylation during acute hypertrophic stress and decreased H4K20 trimethylation during sustained ischemic injury and cardiac dysfunction. In addition, we examined publicly available datasets to analyze enzymes that regulate H4K20 methylation and identified one demethylase (KDM7C) and two methyltransferases (KMT5A and SMYD5) which were all upregulated in heart failure patients. This is the first study to examine histone H4K20 trimethylation in the heart and to determine how this post-translational modification is differentially regulated in multiple models of cardiac disease. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=73 SRC="FIGDIR/small/479885v1_ufig1.gif" ALT="Figure 1"> View larger version (25K): org.highwire.dtl.DTLVardef@169abeorg.highwire.dtl.DTLVardef@94bb0org.highwire.dtl.DTLVardef@4812e8org.highwire.dtl.DTLVardef@1d16478_HPS_FORMAT_FIGEXP M_FIG C_FIG
02 /Specification & Classification
Click any tag to browse matching papersReproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The Epigenetic Regulator Histone Demethylase KDM5A is Activated and Pathogenic in a Mouse Model of Heart Failure
Manisha Deogharia, Chitra Lekha Reddy, … Priyatansh Gurha·bioRxiv·Jan 6, 2026
- Chromatin Remodeling by the Histone Methyltransferase SETD2 Drives Lipotoxic Injury in Cardiometabolic Heart Failure with Preserved Ejection Fraction
Sarah Costantino, S. A. Mohammed, … Francesco Paneni·Circulation ResearchPeer-reviewed·Apr 11, 2025
- Distinct epigenetic programs regulate cardiac myocyte development and disease in the human heart in vivo
Ralf Gilsbach, Martin Schwaderer, … Lutz Hein·Nature CommunicationsPeer-reviewed·Jan 22, 2018
- Cardiomyocyte-specific loss of Smyd5 leads to a robust activation of inflammatory signaling and heart failure in mice.
Ryan D. Bia, Samuel M. Hickenlooper, … Sarah Franklin·bioRxiv·Sep 3, 2026
- Histone lysine demethylase inhibition is a disease-modifying therapy for hypertrophic cardiomyopathy
Manjeet Singh, Yan Fan, … Zhi‐Ping Liu·bioRxiv·Aug 17, 2026
- Genome-Wide DNA Methylation Profiling of the Failing Human Heart with Mechanical Unloading Identifies LINC00881 as an Essential Regulator of Calcium Handling in the Cardiomyocyte
Xianghai Liao, Peter J. Kennel, … Veli Kemal Topkara·JCI InsightPeer-reviewed·Jan 19, 2023